Caricamento...
Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis
OBJECTIVE: To quantify comparative effectiveness of interleukin (IL)−12/23 antagonist (ustekinumab), IL-17A antagonists (secukinumab and ixekizumab), PDE4 inhibitor (apremilast) and tumour necrosis factor-alpha (TNF-α) inhibitors (infliximab, etanercept, adalimumab, certolizumab pegol and golimumab)...
Salvato in:
| Pubblicato in: | RMD Open |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMJ Publishing Group
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8055145/ https://ncbi.nlm.nih.gov/pubmed/33863840 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2020-001399 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|